BeiGene, Ltd. (NASDAQ:BGNE) SVP Sells $284,994.20 in Stock

BeiGene, Ltd. (NASDAQ:BGNE) SVP Chan Henry Lee sold 1,202 shares of the company’s stock in a transaction on Monday, September 30th. The shares were sold at an average price of $237.10, for a total transaction of $284,994.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Chan Henry Lee also recently made the following trade(s):

• On Tuesday, July 30th, Chan Henry Lee sold 834 shares of BeiGene stock. The shares were sold at an average price of $160.57, for a total transaction of $133,915.38.

BeiGene Stock Performance

NASDAQ:BGNE opened at $246.04 on Friday. The company has a quick ratio of 1.75, a current ratio of 1.98 and a debt-to-equity ratio of 0.06. BeiGene, Ltd. has a fifty-two week low of $126.97 and a fifty-two week high of $248.16. The stock has a market cap of $23.84 billion, a PE ratio of -32.50 and a beta of 0.62. The firm’s fifty day simple moving average is $195.21 and its 200-day simple moving average is $168.37.

BeiGene (NASDAQ:BGNE) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($1.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.27) by $1.12. BeiGene had a negative net margin of 16.91% and a negative return on equity of 14.93%. The business had revenue of $929.20 million for the quarter, compared to analysts’ expectations of $810.34 million. During the same period in the prior year, the company posted ($3.64) EPS. The business’s revenue for the quarter was up 56.1% on a year-over-year basis. Analysts expect that BeiGene, Ltd. will post -5.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. JMP Securities assumed coverage on shares of BeiGene in a research report on Wednesday, September 18th. They set a “market outperform” rating and a $288.00 price objective for the company. Citigroup upped their price objective on shares of BeiGene from $269.00 to $288.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Bank of America cut their price objective on shares of BeiGene from $180.00 to $152.50 and set a “neutral” rating for the company in a research report on Tuesday, July 9th. Finally, JPMorgan Chase & Co. upped their price objective on shares of BeiGene from $194.00 to $200.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, BeiGene currently has a consensus rating of “Moderate Buy” and an average price target of $241.21.

Hedge Funds Weigh In On BeiGene

Institutional investors and hedge funds have recently made changes to their positions in the stock. Headlands Technologies LLC acquired a new position in shares of BeiGene during the 1st quarter worth $50,000. SG Americas Securities LLC acquired a new stake in BeiGene in the 3rd quarter valued at about $105,000. Benjamin F. Edwards & Company Inc. grew its stake in BeiGene by 51.5% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 821 shares of the company’s stock valued at $128,000 after acquiring an additional 279 shares during the last quarter. Acadian Asset Management LLC grew its stake in BeiGene by 204.1% in the 1st quarter. Acadian Asset Management LLC now owns 1,265 shares of the company’s stock valued at $197,000 after acquiring an additional 849 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. acquired a new stake in BeiGene in the 1st quarter valued at about $209,000. 48.55% of the stock is owned by institutional investors and hedge funds.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.